Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Nope that's personal info, I wouldn't do that

<< Previous

Bullboard Posts

Next >>

Comment by PTBaileyon Jan 20, 2022 11:22am

110 Views

Post# 34337517

RE:Nope that's personal info, I wouldn't do that

"squeaky clean"

Not claiming to be squeaky clean. But I have never in my private or professional life ever treated or spoke to anyone disrespectfully unless they treated me that way.

Check your history of comments to me and you will remember it was you who treated me disrespectfully so don't expect any respect from me in return.

You don't don't get what you don't give.

<< Previous

Bullboard Posts

Next >>

Visionstate set to leverage success in the U.S. market